Loading...
CFMS logo

Conformis, Inc.NasdaqCM:CFMS Stock Report

Market Cap US$17.8m
Share Price
n/a
My Fair Value
n/a
1Y-65.2%
7D0%
1D
Portfolio Value
View

Conformis, Inc.

NasdaqCM:CFMS Stock Report

Market Cap: US$17.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Conformis (CFMS) Stock Overview

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. More details

CFMS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

CFMS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Conformis, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Conformis
Historical stock prices
Current Share PriceUS$2.26
52 Week HighUS$7.25
52 Week LowUS$1.05
Beta1.39
1 Month Change0.44%
3 Month Change96.52%
1 Year Change-65.23%
3 Year Change-87.44%
5 Year Change-91.93%
Change since IPO-99.53%

Recent News & Updates

Recent updates

Seeking Alpha Sep 13

Conformis stock jumps 17% aftermarket on FDA 510(k) clearance for Actera hip system

Conformis (NASDAQ:CFMS) stock jumped ~17% after hours on Tuesday after the firm received 510(k) clearance from the U.S. Food and Drug Administration for its Actera hip system. Actera uses an advanced tri-taper femur stem design to facilitate a minimally invasive approach similar to direct anterior approach. CFMS will introduce Actera under a limited market release in select U.S. markets, expected to start in the coming months.
Seeking Alpha Aug 01

Conformis signs agreement with Vizient for personalized orthopedic implants

Medical device firm Conformis (NASDAQ:CFMS) said it had entered into a multi-year agreement with Vizient to offer its personalized orthopedic implants. (CFMS) is trading 5.9% higher after the bell. The agreement gives access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers.
Analysis Article Jan 11

Investors Will Want Conformis' (NASDAQ:CFMS) Growth In ROCE To Persist

If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...
Analysis Article Dec 21

We Think Conformis (NASDAQ:CFMS) Can Stay On Top Of Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Nov 11

What Does Conformis, Inc.'s (NASDAQ:CFMS) Share Price Indicate?

Conformis, Inc. ( NASDAQ:CFMS ), is not the largest company out there, but it received a lot of attention from a...
Analysis Article Sep 16

Is Conformis (NASDAQ:CFMS) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha Sep 04

Conformis: Emerging Surgical Implant Developer

Conformis is a small company developing knee and hip replacement implants. They have recent collaboration deals with major players. The company has a decent cash balance, but revenue growth is impacted by the pandemic.
Analysis Article Aug 11

Shareholders Shouldn’t Be Too Comfortable With Conformis' (NASDAQ:CFMS) Strong Earnings

Strong earnings weren't enough to please Conformis, Inc.'s ( NASDAQ:CFMS ) shareholders over the last week. Our...
Analysis Article Aug 10

Party Time: Brokers Just Made Major Increases To Their Conformis, Inc. (NASDAQ:CFMS) Earnings Forecasts

Celebrations may be in order for Conformis, Inc. ( NASDAQ:CFMS ) shareholders, with the analysts delivering a...
Analysis Article May 18

Increases to Conformis, Inc.'s (NASDAQ:CFMS) CEO Compensation Might Cool off for now

In the past three years, the share price of Conformis, Inc. ( NASDAQ:CFMS ) has struggled to grow and now shareholders...
Analysis Article May 11

Analysts Just Shipped An Incredible Upgrade To Their Conformis, Inc. (NASDAQ:CFMS) Estimates

Conformis, Inc. ( NASDAQ:CFMS ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article May 08

Is Conformis (NASDAQ:CFMS) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Jan 16

Is Conformis (NASDAQ:CFMS) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Shareholder Returns

CFMSUS Medical EquipmentUS Market
7D0%-1.1%2.3%
1Y-65.2%-18.8%25.5%

Return vs Industry: CFMS underperformed the US Medical Equipment industry which returned 3.9% over the past year.

Return vs Market: CFMS underperformed the US Market which returned 11.1% over the past year.

Price Volatility

Is CFMS's price volatile compared to industry and market?
CFMS volatility
CFMS Average Weekly Movement25.0%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CFMS's share price has been volatile over the past 3 months.

Volatility Over Time: CFMS's weekly volatility has increased from 20% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004295Mark Augustiwww.conformis.com

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation.

Conformis, Inc. Fundamentals Summary

How do Conformis's earnings and revenue compare to its market cap?
CFMS fundamental statistics
Market capUS$17.80m
Earnings (TTM)-US$41.50m
Revenue (TTM)US$57.06m
0.3x
P/S Ratio
-0.4x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CFMS income statement (TTM)
RevenueUS$57.06m
Cost of RevenueUS$38.12m
Gross ProfitUS$18.95m
Other ExpensesUS$60.45m
Earnings-US$41.50m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.27
Gross Margin33.21%
Net Profit Margin-72.73%
Debt/Equity Ratio64.4%

How did CFMS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/06 04:29
End of Day Share Price 2023/09/01 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Conformis, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory ChodaczekB. Riley Securities, Inc.
Michael GormanBTIG
Kyle RoseCanaccord Genuity